STATEMENT OF CLARIFICATIONLifecare AS' Board would like to clarify and substantiate the notice published on the stock exchange on15 January 2020 :Lifecare AS andIMS Capital Partners GmbH have establishedDigital Diagnostics AG to completeLifecare AS' sensor technology, Sencell. The agreement between the parties entails thatIMS Capital Partners GmbH will finance the completion of Sencell, so thatLifecare AS does not need the planned capital increase in the second half of 2020.Lifecare AS keeps all its rights to its existing IP and has full access to future IP. ByIMS Capital Partners GmbH investingEUR 7,500,000 as working capital inDigital Diagnostics AG , Sencell will be further developed and completed. In return,Lifecare AS will giveDigital Diagnostics AG a license agreement forLifecare AS' technology and IP in all business areas beyondLifecare AS' business area (long-term continuous glucose monitoring of patients with diabetes type 1 and 2). The license is not exclusive toDigital Diagnostics AG , butDigital Diagnostics AG expects great value creation as a result of immediate access to the Lifecare technology. This value creation will benefit all shareholders.Digital Diagnostics AG will be owned 50,1 % byIMS Capital Partners GmbH , 25 % byLifecare AS and 24,9 % by the company's employees and Board. WhenLifecare AS' sensor technology is developed,Lifecare AS will have full ownership of the original IP that has been developed up until15 January 2020 .Lifecare AS will also have unlimited rights to utilize all technology and IP developed through the cooperation withDigital Diagnostics AG , for use withinLifecare AS' business area. ForLifecare AS' shareholders the joint venture withIMS Capital Partners GmbH entails: oLifecare AS' costs to further develop Sencell is covered throughDigital Diagnostics AG , which is financed byIMS Capital Partners GmbH . o Therefore, there is no need for the planned capital increase inLifecare AS in the second half of 2020. o Through a 25% ownership inDigital Diagnostics AG ,Lifecare AS' shareholders will have the opportunity to be part of the further value creation inDigital Diagnostics AG . oLifecare AS' business continues as planned, with significantly reduced costs. o The shareholder composition inLifecare AS will not change as a result of the agreement.IMS Capital Partners GmbH will not get ownership inLifecare AS .
Click here for more information
© Oslo Bors ASA, source